GlobeNewswire Clinical StudiesOriginal article
WallabyPhenox Announces First U.S. Patient Treated with p48 & p64 MW HPC Flow Modulation Devices in PIANO IDE Trial
Trial Startp48 MW HPC Flow Modulation Devicep64 MW HPC Flow Modulation DevicePositive
AI Analysis
Summary
WallabyPhenox announced the first U.S. patient treatment with its p48 and p64 MW HPC flow diverter devices in the PIANO IDE trial for intracranial aneurysms, marking trial initiation.
Clinical Trial Data
Patients
1
Outcome Details
First U.S. patient treated in PIANO IDE trial
Importance:4/10
Sentiment:
0.50
clinical trialmedical devicesneurovascularIDE trialintracranial aneurysm
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on March 20, 2026 12:30 PM